Conjugate Vaccines
Concept And Mechanism
- Converts T-cell independent polysaccharide antigens into T-cell dependent antigens.
- Involves covalent linkage of bacterial capsular polysaccharide to specific carrier protein.
- Recruits helper T-cells for enhanced immune activation.
- Induces robust germinal center reactions.
- Promotes B-cell proliferation, affinity maturation, and isotype class switching.
- Generates long-lasting memory B cells.
- Elicits strong anamnestic response upon subsequent exposure.
Comparative Profile
| Feature | Polysaccharide Vaccine | Conjugate Vaccine |
|---|---|---|
| Antigen Recognition | Recognised by B cells independently; lacks T-cell help. | Recognized by B and T cells; T-cell dependent. |
| Target Population | Poorly immunogenic below 2 years of age. | Highly immunogenic and effective in early infancy. |
| Antibody Production | Chiefly induces low-titer immunoglobulin M. | Induces high-titer immunoglobulin M and immunoglobulin G. |
| Memory Cells | Fails to induce memory B cells. | Induces robust immunological memory. |
| Duration Of Protection | Brief protection requiring frequent revaccination. | Longer, consistent, and sustained protection. |
| Booster Response | Poor response; potential for hyporesponsiveness. | Satisfactory and robust anamnestic response. |
| Herd Immunity | Lacks effect on nasopharyngeal carriage; provides no herd immunity. | Significantly reduces nasopharyngeal carriage; provides excellent herd immunity. |
Carrier Proteins
- Tetanus toxoid utilizes detoxified tetanus toxin.
- Diphtheria toxoid incorporates detoxified diphtheria toxin.
- Cross-reactive material 197 represents nontoxic mutant diphtheria toxin.
- Outer membrane protein derived from Neisseria meningitidis vesicles.
- Protein D extracted from non-typeable Haemophilus influenzae.
Common Clinical Examples
- Haemophilus influenzae type b conjugate vaccine utilizes tetanus toxoid, diphtheria toxoid, cross-reactive material 197, or outer membrane protein.
- Pneumococcal conjugate vaccines include 10-valent, 13-valent, 14-valent, and 20-valent formulations.
- Typhoid conjugate vaccine utilizes tetanus toxoid or cross-reactive material 197 carrier proteins.
- Meningococcal conjugate vaccines exist in monovalent, quadrivalent, and pentavalent formulations.